Pfizer reported strong financial and operational performance in Q2 2025, driven by revenue growth, R&D advancements, and cost efficiencies. However, challenges remain with certain product lines and potential impacts from ongoing policy discussions. While the outlook is positive, uncertainties in COVID-19 revenues and geopolitical factors persist.

Company Guidance -

Q3 2025

During Pfizer's Second Quarter 2025 Earnings Conference Call, the company announced an increase in its adjusted diluted EPS guidance for the full year, reflecting strong year-to-date performance. Pfizer's revenue for the quarter was reported at $14.7 billion, a 10% operational increase, while adjusted diluted earnings per share were $0.78, surpassing expectations due to robust top-line performance and cost management. The call highlighted significant growth in various product lines, including a 21% year-over-year operational growth for the Vyndaqel family and a 38% rise for Padcev. The company is also focusing on expanding its R&D portfolio and revealed ongoing advancements in its pipeline, such as positive results from Elrexfio and ongoing Phase III trials for Sigvotatug Vedotin. The call emphasized Pfizer's strategic priorities, including technological advancements to enhance margins and productivity gains, positioning the company for continued growth and value creation for patients and shareholders.

Record Revenue Growth

Second quarter 2025 revenue increased 10% operationally to $14.7 billion, driven by strong performance in key products like Vyndaqel, Comirnaty, PAXLOVID, Padcev, and Eliquis.

Strong R&D Pipeline Progress

Significant advancements in the R&D pipeline with promising developments in Elrexfio, Sigvotatug Vedotin, and Hympavzi, highlighting potential growth in oncology and hematology markets.

Improved Financial Outlook

Pfizer raised its full-year adjusted EPS guidance due to strong year-to-date performance and favorable foreign exchange impacts.

Operational and Cost Efficiency

Total adjusted operating expenses decreased 8% operationally, driven by reduced marketing spend and pipeline optimization, leading to robust operating margins.

Successful Commercial Strategy

Market leadership maintained in key products like Eliquis and Vyndaqel, with strong international growth and effective engagement strategies.

Pfizer (PFE) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PFE Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 04, 2025	2025 (Q3)	0.74 / -	1.06	―	―	―
Aug 06, 2025	2025 (Q2)	0.58 / 0.78	0.6	30.00% (+0.18)
Apr 29, 2025	2025 (Q1)	0.67 / 0.92	0.82	12.20% (+0.10)
Feb 04, 2025	2024 (Q4)	0.47 / 0.63	0.1	530.00% (+0.53)
Oct 29, 2024	2024 (Q3)	0.61 / 1.06	-0.17	723.53% (+1.23)
Jul 30, 2024	2024 (Q2)	0.46 / 0.60	0.67	-10.45% (-0.07)
May 01, 2024	2024 (Q1)	0.52 / 0.82	1.23	-33.33% (-0.41)
Jan 30, 2024	2023 (Q4)	-0.16 / 0.10	1.14	-91.23% (-1.04)
Oct 31, 2023	2023 (Q3)	-0.08 / -0.17	1.78	-109.55% (-1.95)
Aug 01, 2023	2023 (Q2)	0.57 / 0.67	2.04	-67.16% (-1.37)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PFE Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$24.75	$23.93	-3.31%
Apr 29, 2025	$22.23	$22.95	+3.24%
Feb 04, 2025	$25.27	$24.96	-1.23%
Oct 29, 2024	$26.97	$26.59	-1.41%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.